Podcasts about pharmacyclics llc

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WHH865. CME/MOC/AAPA/IPCE credit will be available until January 5, 2026.Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Based Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/THK865. CME/MOC/NCPD/CPE credit will be available until October 3, 2025.Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/THK865. CME/MOC/NCPD/CPE credit will be available until October 3, 2025.Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/THK865. CME/MOC/NCPD/CPE credit will be available until October 3, 2025.Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/THK865. CME/MOC/NCPD/CPE credit will be available until October 3, 2025.Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/THK865. CME/MOC/NCPD/CPE credit will be available until October 3, 2025.Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/THK865. CME/MOC/NCPD/CPE credit will be available until October 3, 2025.Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJohn C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.Other Financial or Material Support in the form of patents for Ohio State University.Faculty/PlannerDaniel Addison, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.Faculty/PlannerMatthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.Honoraria from Aptitude Health; Bio Ascend; and Curio Science.Other Financial or Material Support in the form of Royalties from Up-to-Date.Faculty/PlannerJennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.Faculty/PlannerPaolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

Tung Wynn, MD, University of Florida, Gainesville, FL and Braulio Hernandez Recorded on June 10, 2023 Join Dr. Tung Wynn from the University of Florida, and Braulio Hernandez, a childhood cancer advocate and AYA survivor of Hodgkin Lymphoma, as they discuss the unique experiences of adolescents and young adults from active treatment to survivorship. Dr. Wynn and Braulio reflect on the physical and psychosocial long-term and late effects of treatment, strategies to support survivors and their families, survivorship guidelines, follow-up care coordination, and resources for clinical staff and for survivors. Listen to this engaging conversation today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Merck & Co. Inc., Pharmacyclics LLC, An AbbVie Company & Janssen Biotech, Inc.

In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCLUpdated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCLResults from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLLPreliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapiesPresenters:Tycel J. Phillips, MD Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow TransplantationAssociate Professor of MedicineUniversity of Michigan Rogel Cancer Center Ann Arbor, MichiganAmy Goodrich, RN, MSN, CRNP-ACResearch Associate, Department of MedicineJohns Hopkins UniversityNurse Practitioner, Department of MedicineThe Sidney Kimmel Comprehensive Cancer CenterBaltimore, MarylandContent supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Link to full program, including a downloadable highlights slideset:https://bit.ly/3yufCU4

The use of oral therapies for chronic lymphocytic leukemia has had a great impact on patient outcomes and quality of life. Pharmacists can play a key role in assisting with therapy selection, education for patients and the healthcare team, and also managing adverse effects for patients receiving these therapies. Objectives Differentiate novel therapies for the treatment of chronic lymphocytic leukemia (CLL) by pharmacologic properties and special considerations for use Associate drug therapy and safety and efficacy information with treatment selection for patients with CLL Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of faculty and disclosures:  Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of faculty and disclosures:  Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of faculty and disclosures:  Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

The use of oral therapies for chronic lymphocytic leukemia has had a great impact on patient outcomes and quality of life. Pharmacists can play a key role in assisting with therapy selection, education for patients and the healthcare team, and also managing adverse effects for patients receiving these therapies. Objectives Differentiate novel therapies for the treatment of chronic lymphocytic leukemia (CLL) by pharmacologic properties and special considerations for use Associate drug therapy and safety and efficacy information with treatment selection for patients with CLL Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Introduction of faculty and disclosures:  Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kevin C. Oeffinger, MD, FASCO, Duke University Medical Center, Durham, NC Recorded on June 9, 2022 Children diagnosed with cancer are a heterogenous population experiencing difference cancer diagnoses and therapies. Each journey presents its own physical, emotional, and psychosocial challenges that healthcare providers need to be attentive to. In this episode, Dr. Kevin Oeffinger, from Duke University in Durham, North Carolina, joins us to discuss the history of pediatric survivorship, physical, long-term, and late effects of treatment, including fertility considerations, strategies to support the survivor through psychosocial and cognitive effects, following a survivorship care plan, symptom monitoring, follow-up care, and so much more. Tune in to this important conversation today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company and Janssen Biotech, Inc.

Educational Objective Identify best practices for managing toxicities associated with therapies for the treatment of Waldenström macroglobulinemia   Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan Faculty has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-457-H01-P. The activity is available for CE credit through June 20, 2022. This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objective Identify best practices for managing toxicities associated with therapies for the treatment of Waldenström macroglobulinemia   Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan Faculty has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-457-H01-P. The activity is available for CE credit through June 20, 2022. This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objective Identify best practices for managing toxicities associated with therapies for the treatment of Waldenström macroglobulinemia   Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan Faculty has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-457-H01-P. The activity is available for CE credit through June 20, 2022. This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education™ (PTCE) provides industry-leading pharmacy CE to retail, oncology, managed care, specialty, and health-system pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Podcast 1: Waldenström Macroglobulinemia and Treatment Advancements with the Use of BTK Inhibitors Educational Objectives ·             Outline the pathophysiology of Waldenström macroglobulinemia (WM) and its connection to use of new and emerging drug therapies ·             Review clinical guidelines and treatment selection in patients with WM Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan   Faculty has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-441-H01-P. The activity is available for CE credit through June 13, 2022.  This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education™ (PTCE) provides industry-leading pharmacy CE to retail, oncology, managed care, specialty, and health-system pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Podcast 1: Waldenström Macroglobulinemia and Treatment Advancements with the Use of BTK Inhibitors Educational Objectives ·             Outline the pathophysiology of Waldenström macroglobulinemia (WM) and its connection to use of new and emerging drug therapies ·             Review clinical guidelines and treatment selection in patients with WM Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan   Faculty has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-441-H01-P. The activity is available for CE credit through June 13, 2022.  This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacy Times Continuing Education™ (PTCE) provides industry-leading pharmacy CE to retail, oncology, managed care, specialty, and health-system pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Podcast 1: Waldenström Macroglobulinemia and Treatment Advancements with the Use of BTK Inhibitors Educational Objectives ·             Outline the pathophysiology of Waldenström macroglobulinemia (WM) and its connection to use of new and emerging drug therapies ·             Review clinical guidelines and treatment selection in patients with WM Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan   Faculty has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-441-H01-P. The activity is available for CE credit through June 13, 2022.  This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

Maria Alma Rodriguez, MD, MACP, CMQ, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on October 21, 2021 In this episode, Dr. Maria Alma Rodriguez from The University of Texas MD Anderson Cancer Center, joins us in discussing the long-term and late effects of cancer treatment, including strategies to support survivors with physical and psychosocial effects. Dr. Rodriguez describes barriers to follow-up care, including why some patients may be lost to this process, challenges to following a cancer survivorship plan, the importance of follow-up care coordination, and how the COVID-19 pandemic has impacted survivorship care. Join us today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company & Janssen Biotech, Inc.

Implementing Digital Technology Tools within Health-Systems for Improving Adherence and Patient Support Educational Objectives: At the completion of this activity, participants will be able to: Define the pharmacist's role in implementing digital and telemedicine technologies within the health system to improve adherence and provide remote patient monitoring and management. Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan He has no relevant financial relationships with commercial interests to disclose. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit. Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part2 This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Foundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects Educational Objectives: At the completion of this activity, participants will be able to: Outline the efficacy of oral BTK inhibitors across B-cell malignancies including a focus on emerging clinical data Recognize pharmacists' responsibilities for monitoring and managing cardiac adverse effects specific to different health-system practice types Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan He has no relevant financial relationships with commercial interests to disclose. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit. Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part1 This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Foundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects Educational Objectives: At the completion of this activity, participants will be able to: Outline the efficacy of oral BTK inhibitors across B-cell malignancies including a focus on emerging clinical data Recognize pharmacists' responsibilities for monitoring and managing cardiac adverse effects specific to different health-system practice types Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan He has no relevant financial relationships with commercial interests to disclose. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit. Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part1 This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Implementing Digital Technology Tools within Health-Systems for Improving Adherence and Patient Support Educational Objectives: At the completion of this activity, participants will be able to: Define the pharmacist's role in implementing digital and telemedicine technologies within the health system to improve adherence and provide remote patient monitoring and management. Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan He has no relevant financial relationships with commercial interests to disclose. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit. Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part2 This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Optimizing Safety and Efficacy of BTK Inhibitors within the Health System with the Use of Digital Strategies Foundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects We will outline the efficacy of oral BTK inhibitors across B-cell malignancies including a focus on emerging clinical data.  We also discuss and recognize pharmacists’ responsibilities for monitoring and managing cardiac adverse effects specific to different health-system practice types.  Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan He has no relevant financial relationships with commercial interests to disclose. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 5 contact hours of knowledge-based credit. This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene. See omnystudio.com/listener for privacy information.

Optimizing Safety and Efficacy of BTK Inhibitors within the Health System with the Use of Digital Strategies Foundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects We will define the pharmacist’s role in implementing digital and telemedicine technologies within the health system to improve adherence and provide remote patient monitoring and management. Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan He has no relevant financial relationships with commercial interests to disclose. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 5 contact hours of knowledge-based credit. This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene. See omnystudio.com/listener for privacy information.